Triple-negative breast cancer (TNBC), which accounts for about 15% of breast cancer cases, is defined as estrogen receptor (ER)-negative, progesterone receptor (PgR)-negative, and human epidermal receptor 2 (HER2)-negative disease. This evidence concerns the gene ESR1 and breast carcinoma.